Pasithea Therapeutics Corp.KTTA
Price (close)
$0.51
Market cap
$17.2M
P/E
—
Revenue (TTM)
—
Net income
-$21.3M
Dividend yield
—
1-year total return
-27.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What Pasithea Therapeutics Corp. does.
research and development of innovative treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous
with a focus on our lead product candidate, PAS-004, a next-generation macrocyclic (as defined below) Mitogen-Activated Protein Kinase
(“MEK”) inhibitor, that we believe may address the limitations and liabilities associated with existing drugs with a similar
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $15,062 | $486,559 | — | — | — |
| Net income | — | -$2.2M | -$13.9M | -$16.0M | -$13.9M | -$20.4M |
| Free cash flow | — | -$3.2M | -$14.7M | -$12.8M | — | — |
More on KTTA.
- Pasithea Therapeutics Corp. summary
- Pasithea Therapeutics Corp. financial statements
- Pasithea Therapeutics Corp. key metrics
- Pasithea Therapeutics Corp. health scores and style box
- Pasithea Therapeutics Corp. earnings
- Pasithea Therapeutics Corp. dividends
- Pasithea Therapeutics Corp. valuation
- Pasithea Therapeutics Corp. ownership and insiders
- Pasithea Therapeutics Corp. peers
Figures from Pasithea Therapeutics Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.